NCT03717688

The Effects of Neprilysin on Glucagon-like Peptide-1

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Nicolai Jacob Wewer Albrechtsen · Academic / Other
• Sex: Male
• Age: 18 Years – 30 Years
• Healthy volunteers: Accepted

Summary

In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor

Detailed description

Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the degradation of GLP-1 but if this is the case in humans is unknown. We therefore administered a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin 100mg the night before and 100mg 2 hours before), both, or place, to nine healthy men during a standardized meal and measured plasma concentrations of GLP-1

Conditions

• Diabetes
• Heart Failure

Interventions

Type	Name	Description
DRUG	Entresto	Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan
DRUG	Sitagliptin 100mg	2 x 100mg sitagliptin as single dose.
DRUG	Placebos	No treatment

Timeline

• Start date: 2018-05-17
• Primary completion: 2019-02-01
• Completion: 2019-05-14
• First posted: 2018-10-24
• Last updated: 2019-07-08

Locations

1 site across 1 country: Denmark